Hence, responding to pembrolizumab + TP with reduced production of MCP-1, IFN-γ, and IL-6 might reflect the presence of a well-functioning intratumoral immune infiltrate able to attack the cancerous epithelial cells in HNSCC. Here, CCL2 is linked to head and neck squamous cell carcinoma.